drugset

drugset / Trial / NCT03465709

Pegcetacoplan (APL-2) in Neovascular AMD

NCT03465709 ↗

Phase 1/2 Terminated 17 enrolled Apellis Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD

Timeline

Start: 2018-02-14
Primary completion: 2019-04-05
Completion: 2019-04-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegcetacoplan	Peptide	—	Intravitreal

Indications